## SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020 Email: shreeganeshbiotechindialtd@gmail.com

Date: 29.05.2019

To, Listing Department,

BSE Limited, P J Tower, Dalal

Street Mumbai-400001 To,

The Secretary, The Calcutta Stock Exchange Ltd,

7, Lyons Range, Kolkata - 700001 To,

Head - Listing

Metropolitan Stock Exchange

of India Limited

Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel Bandra Kurla Complex, Bandra

(E),

Mumbai – 400098

Scrip Code: 539470 Scrip Code: 29221

**Scrip Code: SHREEGANES** 

Dear Sir/Madam,

Sub: Audited Financial Result for quarter ending 31st March, 2019 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith audited financial result for quarter ended 31st March, 2019.

Kindly take the same on your record and oblige.

Thanking You,

Yours faithfully,

FOR, SHREE GANESH BIOTECH (INDIA) LTD

DIRECTOR/ AUTHORIZED SIGNATORY

Shree Ganesh Biotech (India) Ltd

CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020

Email:- shreeganeshbiotechindialtd@gmail.com

Statement of Audited Financial Results for the Quarter & Year Ended March 31, 2019

	The state of the s	and the first operation of the public	PRESIDENCE SERVER DESIGNATION DE L'ANNE DE L'A			(Rs. In la
no.	Particulars	Quarter Ended 31 Mar 2019	Quarter Ended 31 Dec 2018	Quarter Ended 31 Mar 2018	Previous Year Ended 31 Mar 2018	Current Year Ended 31 Mar 2019
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	INCOME					
(a) (b)	Revenue from Operations Other Income	192.32	164.43	118.18	785.76	586.8
11	Total Income from Operations (Net)	192.32	164.43	118.18	785.76	586.8
2	EXPENSES					
(a)	Cost of raw material consumed			75.03	336.53	
b)	Purchase of stock-in-trade	105.40	92.30	Control of the Section St. Control of The Sectio	provident, and till bell many tributes and claimed to be an in the later of the same of the party of the later of the	335.
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade					
d)	Employee benefit expense	3.64	1.20	7.36	9.66	8.
e)	Depreciation and amortization expense	3.04	1.20	7.30	9.00	0.
f)	Other expenses	11.85	13.56	20.25	89.53	63.
1)		120.89		700000000		
	Total Expenses	120.89	107.06	102.64	435.72	407.
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	71.43	57.37	15.54	350.04	178.
4	Other Income	-	-			
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	71.43	57.37	15.54	350.04	178
5	Finance Costs (Net)	-			-	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	71.43	57.37	15.54	350.04	178.
8	Exceptional Items	-	-	-	-	
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	71.43	57.37	15.54	350.04	178.
10	Tax Expense	-		-	-	
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	71.43	57.37	15.54	350.04	178.
12	Other Comprehensive Income (net of tax )	A DESCRIPTION OF THE PARTY OF T		AND STREET	Continues to the second	estra i volumentamini tanica.
13	Total Comprehensive Income for the period (11 $\pm$ 12)	71.43	57.37	15.54	350.04	178.
14	Paid-up equity share capital (Face Value of Rs.10/- each)	1,993.12	1,993.12	183.12	183.12	1,993
5	Other Equity				2,103.84	3,731
6.i	Earnings Per Share (of Rs. 10/- each) (not annualised):					
	(a) Basic	0.36	0.29	0.85	19.12	0
	(b) Diluted	0.36	0.29	0.85	19.12	0



# Shree Ganesh Biotech (India) Ltd CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020 Email:- shreeganeshbiotechindialtd@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities	As at 31st March, 2019	(Rs. in Lakhs) As at 31st March, 2018	
Particulars	Audited	Audited	
ASSETS			
1 Non-current assets			
Property, plant and equipment	0.57	0.1	
Capital work-in-progress			
Other intangible assets			
Investments in subsidiaries, associates and joint ventures Financial assets			
Investments			
Loans			
Other financial assets			
Income Tax assets (net)			
Deferred tax assets (net)			
Other non-current assets			
Sub-total - Non-Current Assets	0.57	0.1	
2 Current assets		and the state of t	
Inventories			
Financial assets		-	
Investments		4 ( )	
Trade receivables	1,916.11	1,351.8	
Cash and cash equivalents	3.40 0.63	1.5	
Bank balances other than Cash and Cash equivalents above Loans, Current	4.484.69	1,278.3	
Other financial assets	4,484.09	1,276	
Other current assets	3.17	3.1	
Assets classified as held for sale			
Sub-total - Current Assets	6,408.00	2,636,1	
TOTAL - ASSETS	6,408.57	2,636.2	
EQUITY AND LIABILITIES			
1 Equity Equity Share capital	1,993.12	183.	
Other equity	3,730.83	2,103.8	
Sub-total - Shareholders' funds	5,723.95	2,286.9	
2 LIABILITIES		Color of the Color	
2 LIABILITIES Non-current liabilities			
Financial liabilities			
Borrowings, non-Current			
Provisions	-		
Income tax liabilities (net)			
Other non-current liabilities		-	
Sub-total - Non-current liabilities	<u> </u>	-	
3 Current liabilities	and the state of the secretary and the second of the secon		
Financial liabilities			
Borrowings, Current	19.03	19.	
Trade payables, Current	665.50	220	
Other financial liabilities Other current liabilities	665.59	330.2	
Provisions		0.0	
Current tax liabilities (net)			
Sub-total - Current liabilities	684.62	349,2	



### Shree Ganesh Biotech (India) Ltd

CIN:-L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata-700020 Email:- shreeganeshbiotechindialtd@gmail.com

### Notes:

- The format of Quarterly results are prescribed in SEBI circular Ref. CIR/CFD/FAC/62/2016 dated July 05,2016 has been modified to comply with requirements of SEBI's crcular dated 5th July, 2016, Ind AS and Schedule III (Division II) of Companies Act, 2013 applicable to companies that are required comply with IND-AS.
- Figures of Quarter ending 31/03/2019 are the balancing figures between audited figures for the full financial year and published year to date figures up to the third quarter of the financial year of the company.
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 29, 2019. The Statutory Auditors have carried out a limited review of the above financial result.
- 4 Company has only one segment and hence no separate segment result has been given.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 6 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

For Shice Cancal Biotech (India) Ltd.

Director/Compliance Office

Carrella

Place: Kolakata Date: 29th May, 2019





Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of SHREE GANESH BIO-TECH (INDIA) LIMITED

We have audited the quarterly financial results of SHREE GANESH BIO-TECH (INDIA) LIMITED for the quarter and year ended 31<sup>st</sup> March, 2019 and the year to date results for the period 1<sup>st</sup> April 2018 to 31<sup>st</sup> March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

 (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March, 2019 as well as the year to date results for the period from 1<sup>st</sup> April 2018 to 31<sup>st</sup> March 2019.

101589W

For, BIPIN & CO.

CHARTERED ACCOUNTANTS

FRN: 101509 W

CA AMIT SHAH PARTNER

M. No.: 126337 Place: Vadodara Date: 29/05/2019

Office: 304, Sumangal Chamber, Jamboo Bet, Dandia Bazar, Vadodara - 390 001, Ph.: 0265-2458666, M: 094263 13900

Email: amit\_d\_shah@rediffmail.com

Head Office: 302, Centre Point, R. C. Dutt Road, Alkapuri, Vadodara - 390 007.